بدائل البحث:
code implementation » model implementation (توسيع البحث), time implementation (توسيع البحث), pre implementation (توسيع البحث)
code implementation » model implementation (توسيع البحث), time implementation (توسيع البحث), pre implementation (توسيع البحث)
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
Table_2_BayesPI-BAR2: A New Python Package for Predicting Functional Non-coding Mutations in Cancer Patient Cohorts.docx
منشور في 2019"…It is evaluated in follicular lymphoma and skin cancer patients, by focusing on sequence variants in gene promoter regions. BayesPI-BAR2 is a useful tool for predicting functional non-coding mutations in whole genome sequencing data: it allows identification of novel transcription factors (TFs) whose binding is altered by non-coding mutations in cancer. …"
-
36
-
37
Python code that implements the Hoshen Kopleman algorithm used to identify the clusters shown in Figs 9 and 10.
منشور في 2023"…<p>Python code that implements the Hoshen Kopleman algorithm used to identify the clusters shown in Figs <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0285630#pone.0285630.g009" target="_blank">9</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0285630#pone.0285630.g010" target="_blank">10</a>.…"
-
38
-
39
Secure Python Code Manager: A Tool for Protected Python Code Distribution and Management
منشور في 2024"…</li><li><b>Commercial Distribution</b>: Safely share Python code with clients or customers, implementing advanced <b>Python code protection tools</b> for sales or rentals.…"
-
40
Table_1_BayesPI-BAR2: A New Python Package for Predicting Functional Non-coding Mutations in Cancer Patient Cohorts.xlsx
منشور في 2019"…It is evaluated in follicular lymphoma and skin cancer patients, by focusing on sequence variants in gene promoter regions. BayesPI-BAR2 is a useful tool for predicting functional non-coding mutations in whole genome sequencing data: it allows identification of novel transcription factors (TFs) whose binding is altered by non-coding mutations in cancer. …"